Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CREBBP Mutation as a Culprit for Negative SSTR2 PET in Neuroendocrine Tumors.

Molecular imaging and biology - 1 Oct 2025

Haj-Mirzaian Arvin, Esfahani Shadi A, Mahmood Umar, Heidari Pedram

Abstract excerpt

PURPOSE: This study aimed to elucidate the molecular and genetic factors contributing to negative 68Ga-DOTATATE PET imaging in neuroendocrine tumors (NETs). By integrating whole exome sequencing (WES) and single-cell RNA sequencing (scRNA-seq), we sought to unravel the interplay between negative results of 68Ga-DOTATATE PET and genetic mutations in NETs. METHODS: A total of 18 patients with lung, ileal, or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to CREB-Binding Protein
Share to Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neuroendocrine Tumors

Share to Organometallic Compounds

Share to Positron-Emission Tomography

Share to Positron Emission Tomography Computed Tomography

Share to Receptors, Somatostatin

Source

Open in PubMed Open full text

Identifiers

PMID: 40779286
DOI: 10.1007/s11307-025-02040-1
PMCID: PMC13060772

Genes

SSTR2
CREBBP
MEN1
PTEN
RB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

CREBBP Mutation as a Culprit for Negative SSTR2 PET in Neuroendocrine Tumors.PMID 40779286Read ↗

A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing-tumor as a potential target of peptide receptor imaging and therapySemantic proximity Read ↗

Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.Semantic proximity Read ↗

Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for <sup>18</sup>F-FDG Imaging of PSMA-Suppressed TumorsSemantic proximity Read ↗

Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted TherapySemantic proximity Read ↗

Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.Semantic proximity Read ↗

Identification of Genes Related to 68Ga-DOTATATE Organ Distribution in Homo SapiensSemantic proximity Read ↗

Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.Semantic proximity Read ↗

Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.